

Ihor Gussak · Charles Antzelevitch *Editors*

Arthur A.M. Wilde · Brian D. Powell · Michael J. Ackerman

Win-Kuang Shen *Co-Editors*

Electrical Diseases of the Heart

Volume 2:
Diagnosis and Treatment

Second Edition

 Springer

Electrical Diseases of the Heart

Second Edition

Volume 2: Diagnosis and Treatment

Ihor Gussak and Charles Antzelevitch (Eds.)

Arthur A.M. Wilde, Brian D. Powell, Michael J. Ackerman,
and Win-Kuang Shen (Co-Eds.)

Electrical Diseases of the Heart

Second Edition

Volume 2: Diagnosis and Treatment

 Springer

Editors

Ihor Gussak, MD, PhD, FACC
Ono Pharmaceutical USA
Lawrenceville
NJ, USA

Department of Internal Medicine
University of Medicine and Dentistry
of New Jersey
Robert Wood Johnson Medical School
New Brunswick, NJ
USA

Charles Antzelevitch, PhD, FACC, FAHA,
FHRS
Gordon K. Moe Scholar
Masonic Medical Research Laboratory
Utica, NY
USA

Co-Editors

Arthur A.M. Wilde, MD, PhD, FESC, FAHA
Department of Cardiology, Heart Center
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

Brian D. Powell, MD
Division of Cardiovascular Diseases
Sanger Heart & Vascular Institute
Charlotte, NC
USA

Michael J. Ackerman, MD, PhD, FACC
Department of Medicine
Division of Cardiovascular Diseases
Department of Pediatric and Adolescent
Medicine
Division of Pediatric Cardiology
Department of Molecular Pharmacology
and Experimental Therapeutics
Mayo Clinic
Rochester, MN, USA

Win-Kuang Shen, MD
Division of Cardiovascular Diseases
Department of Medicine
Mayo Clinic College of Medicine
Mayo Clinic Arizona
Phoenix, AZ
USA

ISBN 978-1-4471-4880-7 2nd edition (Vol 1)
e-ISBN 978-1-4471-4881-4 2nd edition (eBook)

ISBN 978-1-4471-4977-4 2nd edition (Vol 2)
e-ISBN 978-1-4471-4978-1 2nd edition (eBook)

ISBN 978-1-84628-853-1 1st edition
e-ISBN 978-1-84628-854-8 1st edition
DOI 10.1007/978-1-4471-4978-1
Springer London Heidelberg New York Dordrecht

Library of Congress Control Number: 2013936435

A catalogue record for this book is available from the British Library
© Springer-Verlag London 2013
First published 2008

This is a revised and expanded edition of Gussak et al *Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention*, published by Springer in [2008].

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

We dedicate this book to the thousands of investigators whose collective works have brought us to this exciting juncture in the history of science and medicine and on whose shoulders we stand. We are proud to dedicate this compendium to these pioneers of cardiac electrophysiology as well as to our mentors, collaborators and fellows who have assisted us in advancing the field and last but certainly not least to our families, whose understanding and support permitted us to dedicate the time and effort needed to formulate this text.

*Ihor Gussak
Charles Antzelevitch*

Foreword

I presented the following “case report” in the preface of the first edition of this book to illustrate the progress in cardiac electrophysiology over a period of 20-odd years. The evolution is still relevant:

She was about 35 years old when she first became my patient in 1975. She had suffered from bouts of a supraventricular tachycardia (SVT) as far back as she could remember. “In the early days,” she recalled, “when I was a kid, they would give me something in the emergency room that elevated my blood pressure and damn near tore my head off. What a headache I would get! But a lot of times it didn’t work. Then they stuck my head in a bucket of cold water and told me to ‘bear down.’ Finally, they would give me more digitalis in my vein until I started vomiting. That usually stopped the SVT.”

But nothing seemed to prevent recurrences. She was on a full dose of digi-toxin and was one of the first to try a β (beta) blocker (propranolol) in the late 1960s. Her episodes were fast, around 220/min, and frightened her terribly, so much so that she would ride the tractor alongside her farmer-husband all day long just to be near him in case she had a recurrence.

Then came one of the first breakthroughs. Gordon Moe had published a “case report” of a dog with probable atrioventricular node reentry (AVNRT), showing that such a tachycardia could be started and stopped by external stimuli. Clinical studies followed (though somewhat belatedly) and replicated such responses in humans. Medtronic developed an implantable pacemaker (5998 RF unit) that was triggered by an external battery-driven stimulator held over the passive receiver to deliver a burst of rapid stimuli to the epicardial electrodes implanted on her right atrium. Magic! She terminated her own SVT with unerring reliability and never precipitated atrial fibrillation. Now a free woman, she no longer needed tractor rides. But she never left her house without the RF generator and always carried a spare battery in her pocket.

Over time she discontinued her medications and gradually stopped coming for return visits because she had complete control of her SVT. About 15 years later she showed up unannounced after one of the wires in her hand held unit fractured and she no longer could stop the SVT. “Could I get her a replacement or send the broken unit for repairs?” she asked. The next day she was in the EP laboratory, had a slow pathway ablation, cure of the AVNRT, and eventual removal of the implanted unit.

This patient benefited from knowledge derived from animal and clinical research, as well as technological discoveries, over a period of some 15–20 years. And hundreds of thousands of patients like her have similarly profited from such advances. The work of basic and clinical scientists continues to uncover complex mechanisms and anatomic sites responsible for these and other arrhythmias, providing understanding ranging from molecular to clinical. Such advances, along with new mapping, imaging and recording modalities, and catheter and ablation innovations, help us toward our goal of translating science into improved patient care. We are also beginning to understand the pervasive role of genetics, not just for the classic inherited syndromes, but also for polygenic diseases such as sudden death in coronary disease and heart failure, and to manipulate genes for therapy.

Once again this book captures this new information, with sections on basic electrophysiology and heritable channelopathies, primary and secondary electrical diseases and sudden cardiac death, diagnostic methods and tools, risk stratification, and treatment. It is a tour de force, and one that is certain to fulfill the reading tastes and intellectual demands of both researchers and clinicians.

Congratulations to the editors and authors for creating the second edition of this popular work.

Indianapolis, IN

Douglas P. Zipes, MD

Preface

In this second edition of *Electrical Disease of the Heart*, our goal was to embrace and highlight the explosion of knowledge that our field has witnessed since the publication of the first edition of this book. Building on the success of our first edition, our approach continues to be one of bridging basic and clinical science in an attempt to meaningfully advance our understanding of heart diseases and identify the knowledge gaps that exist.

Each chapter includes up-to-date results of studies aimed at providing an understanding of the electrical function of the heart in health and disease, established and evidence-based knowledge of clinical outcomes, areas of controversy, and future trends. Our goal is to provide a contemporary and succinct distillation of the state of the art. Although many of the chapters are highly sub-specialized, this book is designed for a broad audience, ranging from medical and graduate students to clinicians and scientists.

The book is the result of a collaboration that has brought together the skills and perspectives of researchers, scientists, and clinicians. We are deeply indebted to our associate editors and to all of the authors for their valuable contributions.

Ihor Gussak
Charles Antzelevitch

Contents

Foreword.	vii
Preface.	ix
Part I Secondary Hereditary and Acquired Cardiac Channelopathies and Sudden Cardiac Death <i>Arthur A.M. Wilde, Michael J. Ackerman, Charles Antzelevitch, and Ihor Gussak</i>	
1 Introduction to Part Three: Cardiac Remodeling <i>N.A. Mark Estes III</i>	3
2 Arrhythmias and Arrhythmia Management in Hypertrophic Cardiomyopathy. <i>J. Martijn Bos, Steve R. Ommen, and Michael J. Ackerman</i>	7
3 Sudden Cardiac Death in Dilated Cardiomyopathy and Skeletal Muscular Dystrophy. <i>Ingrid A.W. van Rijsingen, Anneke J. van der Kooi, and Yigal M. Pinto</i>	25
4 Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia <i>Hugh Calkins and Frank Marcus</i>	41
5 The Wolff-Parkinson-White Syndrome and the Risk of Sudden Death. <i>Michael H. Gollob, Rafeeq Samie, David H. Birnie, Martin S. Green, and Robert M. Gow</i>	55
6 Acquired (Drug-Induced) Long and Short QT Syndromes <i>Rashmi R. Shah and Ihor Gussak</i>	73
7 Acquired Form of Brugada Syndrome. <i>Wataru Shimizu</i>	123

Part II Clinical Rhythmology: Diagnostic Methods and Tools	
<i>Win-Kuang Shen, Michael J. Ackerman, Brian D. Powell, Arthur A.M. Wilde, and Ihor Gussak</i>	
8	Introduction to Part IV: Abnormal Electrical Functions of the Heart and Their Diagnoses in Clinic 141 <i>Benjamin C. Eloff</i>
9	Diagnostic Electrocardiography 145 <i>Preben Bjerregaard</i>
10	Microvolt T Wave Alternans: Mechanisms and Implications for Prediction of Sudden Cardiac Death 159 <i>Florian Rader, Lance D. Wilson, Ottorino Costantini, and David S. Rosenbaum†</i>
11	Heart Rate Variability: Measurements and Risk Stratification 179 <i>Yi Gang</i>
12	Orthostatic Challenge Tests: Active Standing and Head-Up Tilt 197 <i>Louise R.A. Olde Nordkamp, Nynke van Dijk, and Wouter Wieling</i>
13	Signal Averaged ECG 209 <i>Gioia Turitto, David M. Benson, Brian C. Wong, and Nabil El-Sherif</i>
14	Surface Mapping and Magneto-Electrocardiography 223 <i>Satsuki Yamada and Akihiko Kandori</i>
15	Ambulatory Monitoring: (Holter, Event Recorders, External, and Implantable Loop Recorders and Wireless Technology) 239 <i>Rajesh N. Subbiah, Pow-Li Chia, Peter Leong-Sit, Lorne J. Gula, Allan C. Skanes, Raymond Yee, George J. Klein, and Andrew D. Krahn</i>
16	Device Therapy for Remote Patient Management 255 <i>Dwight W. Reynolds, Christina M. Murray, and Robin Germany</i>
17	Invasive Electrophysiologic Testing: Role in Sudden Death Prediction 271 <i>Jan Némec and Win-Kuang Shen</i>
18	Provocative (Drug) Testing in Inherited Arrhythmias 289 <i>Wataru Shimizu and Michael J. Ackerman</i>

†Deceased.

19	Novel Predictors of Sudden Cardiac Death	301
	<i>Sumeet S. Chugh, Rasmus Havmøller, Carmen Teodorescu, Adriana Huertas-Vazquez, Audrey Uy-Evanado, and Kyndaron Reinier</i>	
20	Genetic Testing	315
	<i>David J. Tester and Michael J. Ackerman</i>	
Part III Risk Stratification of Sudden Cardiac Death in Acquired Clinical Conditions		
	<i>Michael J. Ackerman, Brian D. Powell, Arthur A.M. Wilde, Win-Kuang Shen, and Ihor Gussak</i>	
21	Introduction to Part Five: Screening for Risk of Sudden Cardiac Death	335
	<i>John B. Kostis</i>	
22	Risk Stratification for Sudden Death in Patients with Coronary Artery Disease.	339
	<i>Emerson H. Liu, Lilian P. Joventino, and Alfred E. Buxton</i>	
23	Sudden Death in Athletes.	363
	<i>Domenico Corrado, Anna Baritussio, Mariachiara Siciliano, Antonio Pelliccia, Maurizio Schiavon, Cristina Basso, Barry J. Maron, and Gaetano Thiene</i>	
24	Cardiac Channelopathies and Sudden Infant Death Syndrome	381
	<i>Peter J. Schwartz, Marco Stramba-Badiale, John R. Giudicessi, David J. Tester, Lia Crotti, and Michael J. Ackerman</i>	
25	Heart Failure and Sudden Death	395
	<i>Yong-Mei Cha and Win-Kuang Shen</i>	
26	Neurologic Conditions and Sudden Death	413
	<i>David M. Ficker and Elson L. So</i>	
27	Sudden Cardiac Death and Alcohol	425
	<i>Vincent M. Figueredo and Bhaskar Purushottam</i>	
28	Sudden Cardiac Death and Addictive Chemical Substances	441
	<i>Bhaskar Purushottam and Vincent M. Figueredo</i>	
29	Obstructive Sleep Apnea and Sudden Death	461
	<i>Apoor S. Gami and Virend K. Somers</i>	
30	Sudden Cardiac Arrest in Chronic Kidney Disease	475
	<i>Rod Passman, Mai Ots-Rosenberg, Ihor Gussak, and Hiie M. Gussak</i>	

31	Clinical Trials in Sudden Cardiac Death Prevention: Principles and Endpoints.	487
	<i>Andrzej S. Kosinski</i>	
Part IV Treatment and Prevention Modalities		
	<i>Brian D. Powell, Win-Kuang Shen, Michael J. Ackerman, and Ihor Gussak</i>	
32	Introduction to Part IV: Treatment Modalities.	497
	<i>Mark E. Josephson</i>	
33	Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death	501
	<i>Hon-Chi Lee and Kristin T.L. Huang</i>	
34	Non-antiarrhythmic Drugs in Sudden Death Prevention.	525
	<i>Leonard Ilkhanoff, Alan H. Kadish, and Jason T. Jacobson</i>	
35	Non-surgical Treatment and Prevention of Atrial Fibrillation	543
	<i>Patricia Tung and Peter J. Zimetbaum</i>	
36	Surgical Treatment of Atrial Fibrillation.	561
	<i>John M. Stulak and Hartzell V. Schaff</i>	
37	Catheter Ablation for Triggered Ventricular Fibrillation and Polymorphic Ventricular Tachycardia.	577
	<i>Frédéric Sacher, Mélèze Hocini, Sébastien Knecht, Nicolas Derval, Pierre Jaïs, and Michel Haïssaguerre</i>	
38	Catheter Ablation for Scar-Dependent Ventricular Tachycardia.	591
	<i>Roy M. John and William G. Stevenson</i>	
39	The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations	611
	<i>Bruce L. Wilkoff and Sergio G. Thal</i>	
40	Beyond Sudden Death Prevention: Minimizing ICD Shocks and Morbidity, and Optimizing Efficacy	621
	<i>Eyal Nof, Michael Glikson, David Luria, Joseph Gard, and Paul A. Friedman</i>	
41	Pacing and Cardiac Resynchronization.	649
	<i>Robert F. Rea</i>	
	Index	659

Contributors

Michael J. Ackerman MD, PhD, FACC
Department of Medicine,
Division of Cardiovascular Diseases,
Department of Pediatric and Adolescent
Medicine,
Division of Pediatric Cardiology,
Department of Molecular Pharmacology
and Experimental Therapeutics,
Mayo Clinic,
Rochester, MN, USA

Anna Baritussio, MD
Division of Cardiology, Department of Cardiac,
Thoracic and Vascular Sciences,
Padua Medical School,
Padua, Italy

Cristina Basso, MD, PhD
Cardiovascular Pathology,
Department of Cardiac,
Thoracic and Vascular Sciences,
University of Padua Medical School,
Padova, Italy

David M. Benson, MD
Division of Cardiology,
Department of Medicine,
New York Methodist Hospital,
Brooklyn, NY, USA

David H. Birnie, MD
Division of Cardiology,
Department of Medicine,
University of Ottawa Heart Institute,
Ottawa, ON, Canada

Preben Bjerregaard, MD, DMSc
Division of Cardiology, VA Medical Center,
Washington University in St. Louis,
St. Louis, MO, USA

J. Martijn Bos, MD, PhD
Department of Molecular Pharmacology
and Experimental Therapeutics,
Mayo Clinic, Rochester, MN, USA

Alfred E. Buxton, MD
Clinical Electrophysiology Laboratory,
Cardiovascular Division,
Department of Medicine,
Beth Israel Deaconess Medical Center,
Harvard Medical School,
Boston, MA, USA

Hugh Calkins, MD
Department of Cardiology, School of Medicine,
Johns Hopkins University School of Medicine,
Baltimore, MD, USA

Department of Cardiology,
The Johns Hopkins Hospital,
Baltimore, MD, USA

Yong-Mei Cha, MD
Cardiovascular Diseases and Internal Medicine,
Mayo Clinic, Rochester, MN, USA

Pow-Li Chia, MBBS, M Med
Department of Cardiology,
St. Vincent's Hospital,
Sydney, NSW, Australia

Sumeet S. Chugh, MD

The Heart Institute,
Cedars-Sinai Medical Center,
Los Angeles, CA, USA

Domenico Corrado, MD, PhD

Division of Cardiology,
Department of Cardiac,
Thoracic and Vascular Sciences,
University of Padua,
Padova, Italy

Ottorino Costantini, MD

The Heart and Vascular
Center Case Western Reserve
University/ MetroHealth Campus,
Cleveland, OH, USA

Lia Crotti, MD, PhD

Department of Molecular Medicine,
University of Pavia and Fondazione IRCCS
Policlinico S. Matteo,
Pavia, Italy
Department of Cardiology,
University of Pavia and Fondazione IRCCS
Policlinico S. Matteo,
Pavia, Italy

Nicolas Derval, MD

Department of Electrophysiology,
CHU de Bordeaux, Hopital Cardiologique
du Haut Leveque,
Pessac CEDEX, France
IHU LIRYC, INSERM, Bordeaux University,
Bordeaux, France

Nynke van Dijk, MD, PhD

Department of General Practice,
Family Medicine, Academic Medical Center,
University of Amsterdam,
Amsterdam, The Netherlands

Benjamin C. Eloff, PhD

Division of Epidemiology,
Office of Surveillance and Biometrics,
Center for Devices and Radiological Health,
United States Food and
Drug Administration,
Silver Spring, MD, USA

Nabil El-Sherif, MD

Division of Cardiology, Department of Medicine,
New York Harbor Veterans Administration
Healthcare System,
Brooklyn, NY, USA

N.A. Mark Estes III, MD

Department of Medicine,
Tufts University School
of Medicine,
Boston, MA, USA
Tufts Cardiac Arrhythmia Center,
Boston, MA, USA

David M. Ficker, MD, FAAN

Department of Neurology,
College of Medicine,
University of Cincinnati Academic
Health Center,
Cincinnati, OH, USA

Vincent M. Figueredo, MD

Cardiovascular Medicine Department,
Institute for Heart and
Vascular Health,
Einstein Medical Center,
Philadelphia, PA, USA

Paul A. Friedman, MD

Division of Cardiovascular
Medicine,
Mayo Clinic, Rochester,
MN, USA

Apoor S. Gami, MD, MSc

Section of Electrophysiology,
Midwest Heart Specialists,
Elmhurst, IL, USA

Yi Gang, MD, PhD

Division of Clinical Sciences,
Cardiovascular Sciences Research centre,
St. George's, University of London,
London, UK

Joseph Gard, MD

Division of Cardiovascular
Diseases,
Mayo Clinic, Rochester, MN, USA

Robin Germany, MD
 Cardiovascular Division,
 Department of Medicine,
 University of Oklahoma,
 Oklahoma City, OK, USA

John R. Giudicessi, BA
 Divisions of Cardiovascular Diseases
 and Pediatric Cardiology,
 Departments of Medicine,
 Pediatrics, and Molecular Pharmacology &
 Experimental Therapeutics,
 Windland Smith Rice Sudden Death Genomics
 Laboratory, Mayo Clinic,
 Rochester, MN, USA

Michael Glikson, MD
 Davidai Arrhythmia Center,
 Leviev Heart Center,
 Sheba Medical Center
 and Tel Aviv University,
 Tel Hashomer, Israel

Michael H. Gollob, MD
 Arrhythmia Research Laboratory,
 Division of Cardiology,
 Department of Medicine,
 University of Ottawa Heart Institute,
 Ottawa, ON, Canada

Robert M. Gow, MD
 Division of Cardiology,
 Department of Medicine,
 Children's Hospital of Eastern Ontario,
 University of Ottawa,
 Ottawa, ON, Canada

Martin S. Green, MD
 Division of Cardiology,
 Department of Medicine,
 University of Ottawa Heart Institute,
 Ottawa, ON, Canada

Lorne J. Gula, MD
 Division of Cardiology,
 University of Western Ontario,
 London, ON, Canada

Hiie M. Gussak, MD
 Medicine Department,
 UMDNJ, Newark, NJ, USA
 New Jersey Medical School,
 Hackensack University Medical Center,
 Hackensack, NJ, USA

Ihor Gussak, MD, PhD, FACC
 Ono Pharmaceutical USA,
 Lawrenceville, NJ, USA
 Department of Internal Medicine
 University of Medicine and Dentistry
 of New Jersey,
 Robert Wood Johnson Medical School,
 New Brunswick, NJ, USA

Michel Haïssaguerre, MD
 Department of Electrophysiology,
 CHU de Bordeaux, Hopital Cardiologique
 du Haut Leveque,
 Pessac CEDEX, France
 IHU LIRYC, INSERM,
 Bordeaux University,
 Bordeaux, France

Rasmus Havmøller, MD, PhD
 Cedars-Sinai Heart Institute,
 Los Angeles, CA, USA
 Department of Cardiology,
 Karolinska University Hospital,
 Stockholm, Sweden

Mélèze Hocini, MD
 Department of Electrophysiology,
 CHU de Bordeaux, Hopital Cardiologique
 du Haut Leveque,
 Pessac CEDEX, France
 IHU LIRYC, Bordeaux University,
 Bordeaux, France

Kristin T.L. Huang, MD
 Department of Medicine,
 Brigham and Women's Hospital,
 Boston, MA, USA

Adriana Huertas-Vazquez, PhD
 Cedars-Sinai Heart Institute,
 Los Angeles, CA, USA

Leonard Ilkhanoff, MD, MS
Division of Cardiology,
Electrophysiology Section,
Department of Medicine,
Northwestern Memorial Hospital,
Northwestern University,
Chicago, IL, USA

Jason T. Jacobson, MD
Division of Cardiology, Columbia University,
Mount Sinai Medical Center,
Miami Beach, FL, USA

Pierre Jaïs, MD
Department of Electrophysiology,
CHU de Bordeaux, Hopital Cardiologique
du Haut Leveque,
Pessac CEDEX, France
IHU LIRYC, INSERM, Bordeaux University,
Bordeaux, France

Roy M. John, MBBS, PhD
Division of Cardiology,
Department of Medicine,
Brigham and Women's Hospital,
Harvard Medical School,
Boston, MA, USA
Medicine Department, Harvard University,
Boston, MA, USA
Cardiac Arrhythmia Service, SH5,
Brigham and Women's Hospital,
Boston, MA, USA

Mark E. Josephson, MD
Cardiovascular Medicine Division,
Harvard Medical School,
Harvard-Thorndike Electrophysiology Institute
and Arrhythmia Service,
Beth Israel Deaconess Medical Center,
Boston, MA, USA

Lilian P. Joventino, MD
Department of Cardiology,
Wentworth-Douglass Hospital,
Dover, NH, USA

Alan H. Kadish, MD
Office of the President,
New York Medical College,
Valhalla, NY, USA

Akihiko Kandori, PhD(Eng), PhD(Med)
Central Research Laboratory,
Life Science Research Center,
Hitachi Ltd., Tokyo, Japan

George J. Klein, MD
Division of Cardiology,
University of Western Ontario,
London, ON, Canada

Sébastien Knecht, MD
Department of Electrophysiology,
CHU de Bordeaux, Hopital Cardiologique
du Haut Leveque,
Pessac CEDEX, France
IHU LIRYC, INSERM, Bordeaux University,
Bordeaux, France

Anneke J. van der Kooij, MD, PhD
Department of Neurology,
Academic Medical Centre,
Amsterdam, The Netherlands

Andrzej S. Kosinski, PhD
Department of Biostatistics and Bioinformatics,
Duke University School of Medicine,
Duke Clinical Research Institute,
Durham, NC, USA

John B. Kostis, MD
UMDNJ-Robert Wood Johnson Medical School,
Cardiovascular Institute,
New Brunswick, NJ, USA

Andrew D. Krahn, MD
Division of Cardiology, Gordon and Leslie Diamond
Health Care Centre,
University of British Columbia,
Vancouver, BC, Canada

Hon-Chi Lee, MD, PhD
Division of Cardiovascular Diseases,
Department of Internal Medicine,
Mayo Medical School,
Mayo Clinic, Rochester, MN, USA

Peter Leong-Sit, MD
Division of Cardiology,
University of Western Ontario,
London, ON, Canada

Emerson H. Liu, MD

Cardiovascular Division, Medicine Department,
Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, USA

David Luria, MD

Davidai Arrhythmia Center,
Leviev Heart Center,
Sheba Medical Center and Tel Aviv University,
Tel Hashomer, Israel

Frank Marcus, MD

Division of Cardiology,
The University of Arizona,
Sarver Heart Center,
Tucson, AZ, USA

Barry J. Maron, MD

Hypertrophic Cardiomyopathy Center,
Minneapolis Heart Institute Foundation,
Minneapolis, MN, USA

Christina M. Murray, MD

Medicine Department,
Cardiovascular Section,
University of Oklahoma Health Sciences
Center and OU Medical Center,
Oklahoma City, OK, USA

Jan Němec, MD, FACC

Department of Medicine and Clinical Cardiac
Electrophysiology,
Cardiovascular Institute,
University of Pittsburgh,
Pittsburgh, PA, USA

Eyal Nof, MD

Davidai Arrhythmia Center,
Leviev Heart Center,
Sheba Medical Center and Tel Aviv University,
Tel Hashomer, Israel

Louise R.A. Olde Nordkamp, MD

Department of Cardiology,
Heart Failure Research Center,
Academic Medical Center,
University of Amsterdam,
Amsterdam, The Netherlands

Steve R. Ommen, MD

Department of Molecular Pharmacology
and Experimental Therapeutics,
Mayo Clinic, Rochester,
MN, USA

Mai Ots-Rosenberg, MD, PhD

Nephrology Division,
Internal Department,
Tartu University,
Tartu, Estonia

Rod Passman, MD, MSCE

Medicine Department,
Cardiology, Electrophysiology Section,
Northwestern University Feinberg
School of Medicine,
Chicago, IL, USA

Antonio Pelliccia, MD

Department of Medicine,
Institute of Sport Medicine and Science,
Rome, Italy

Yigal M. Pinto, MD, PhD

Heart Failure Research Center,
Heart Center, Academic Medical Center,
Amsterdam, The Netherlands

Bhaskar Purushottam, MD

Cardiovascular Medicine Department,
Institute for Heart and Vascular Health,
Einstein Medical Center,
Philadelphia, PA, USA

Florian Rader, MD, MSc

Cedar Sinai Medical Center,
LA, USA

Robert F. Rea, MD

Internal Medicine,
Cardiovascular Diseases,
Mayo Clinic, Rochester, MN, USA

Kyndaron Reinier, PhD, MPH

Cedars-Sinai Heart Institute,
Los Angeles, CA, USA

Dwight W. Reynolds, MD
 Medicine Department,
 Cardiovascular Section,
 University of Oklahoma Health Sciences
 Center and OU Medical Center,
 Oklahoma City, OK, USA

Ingrid A. W. van Rijsingen, MD
 Heart Failure Research
 Center, Heart Center,
 Academic Medical Center,
 Amsterdam, The Netherlands

David S. Rosenbaum†, MD
 The Heart and Vascular
 Center Case Western Reserve
 University/ MetroHealth Campus,
 Cleveland, OH, USA

Frédéric Sacher, MD
 Department of Electrophysiology,
 CHU de Bordeaux, Hôpital Cardiologique
 du Haut Leveau,
 Pessac CEDEX, France
 IHU LIRYC, INSERM, Bordeaux University,
 Bordeaux, France

Rafeeq Samie, MD
 Division of Cardiology,
 Department of Medicine,
 University of Ottawa Heart Institute,
 Ottawa, ON, Canada

Hartzell V. Schaff, MD
 Cardiovascular Surgery Division,
 Surgery Department, Mayo Clinic,
 Rochester, MN, USA

Maurizio Schiavon, MD
 Department of Social Health,
 Center for Sports Medicine and Physical
 Activity,
 Padua, Italy

Peter J. Schwartz, MD
 Department of Molecular Medicine,
 University of Pavia and Fondazione IRCCS
 Policlinico S. Matteo,
 Pavia, Italy

Department of Cardiology,
 Fondazione IRCCS Policlinico S. Matteo,
 Pavia, Italy

Rashmi R. Shah, BSc, MBBS, MD, FRCP, FFPM
 Rashmi Shah Consultancy Ltd.,
 Gerrards Cross,
 London, UK

Win-Kuang Shen, MD
 Division of Cardiovascular Diseases,
 Department of Medicine,
 Mayo Clinic College of Medicine,
 Mayo Clinic Arizona,
 Phoenix, AZ, USA

Wataru Shimizu, MD, PhD
 Division of Arrhythmia
 and Electrophysiology,
 Department of Cardiovascular Medicine,
 National Cerebral and Cardiovascular Center,
 Suita, Osaka, Japan

Division of Cardiology,
 Department of Internal Medicine,
 Nippon Medical School,
 Bunkyo-ku, Tokyo, Japan

Mariachiara Siciliano, MD
 Division of Cardiology, Department of Cardiac,
 Thoracic and Vascular Sciences,
 Padua Medical School,
 Padua, Italy

Allan C. Skanes, MD
 Division of Cardiology,
 University of Western Ontario,
 London, ON, Canada

Elson L. So, MD
 Department of Neurology, Mayo Clinic,
 Rochester, MN, USA

Virend K. Somers, MD, PhD
 Division of Cardiovascular Diseases
 and Internal Medicine,
 Mayo Clinic College of Medicine,
 Rochester, MN, USA

William G. Stevenson, MD
Division of Cardiology,
Department of Medicine,
Brigham and Women's Hospital,
Harvard Medical School,
Boston, MA, USA
Medicine Department,
Harvard University,
Boston, MA, USA

Marco Stramba-Badiale, MD, PhD
Pediatric Arrhythmias Center,
IRCCS Istituto Auxologico Italiano,
Milan, Italy

John M. Stulak, MD
Cardiovascular Surgery Division,
Surgery Department,
Mayo Clinic, Rochester, MN, USA

Rajesh N. Subbiah, MBBS, PhD
Department of Cardiology,
St. Vincent's Hospital,
University of New South Wales,
Darlinghurst, Sydney,
NSW, Australia

Carmen Teodorescu, MD, PhD
Cedars-Sinai Heart Institute,
Los Angeles, CA, USA

David J. Tester, BS
Cardiovascular Diseases Division,
Department of Medicine, Mayo Clinic,
Rochester, MN, USA

Sergio G. Thal, MD
Cardiology Department,
Cardiac Electrophysiology,
Southern Arizona VA Health Care Center,
Tucson, AZ, USA
Medicine Department,
University of Arizona,
Tucson, AZ, USA

Gaetano Thiene, MD, FRCP
Cardiovascular Pathology, Department of
Cardiac, Thoracic and Vascular Sciences,

University of Padua Medical School,
Padova, Italy

Patricia Tung, MD
Cardiology Division, Medicine Department,
Beth Israel Deaconess Medical Center,
Boston, MA, USA

Gioia Turitto, MD
Division of Cardiology,
Department of Medicine,
New York Methodist Hospital,
Brooklyn, NY, USA

Audrey Uy-Evanado, MD
Cedars-Sinai Heart Institute,
Los Angeles, CA, USA

Wouter Wieling, MD, PhD
Department of Internal Medicine,
Academic Medical Center,
University of Amsterdam,
Amsterdam, The Netherlands

Bruce L. Wilkoff, MD
Department of Cardiovascular Medicine,
Heart and Vascular Institute,
Cleveland Clinic,
Cleveland, OH, USA
Medicine Department,
Cleveland Clinic Lerner College
of Medicine, Case Western
Reserve University,
Cleveland, OH, USA

Lance D. Wilson, MD
The Heart and Vascular
Center Case Western Reserve
University/MetroHealth Campus,
Cleveland, OH, USA

Brian C. Wong, MD
Division of Cardiology,
Department of Medicine,
New York Methodist Hospital,
Brooklyn, NY, USA

Satsuki Yamada, MD, PhD

Division of Cardiovascular Diseases,
Department of Medicine,
Molecular Pharmacology and
Experimental Therapeutics,
and Medical Genetics,
Mayo Clinic, Rochester, MN, USA

Raymond Yee, MD

Division of Cardiology,
University of Western Ontario,
London, ON, Canada

Peter J. Zimetbaum, MD

Cardiology Division,
Medicine Department,
Beth Israel Deaconess Medical Center,
Boston, MA, USA

Douglas P. Zipes, MD

Indiana University School of Medicine,
Krannert Institute of Cardiology;
HeartRhythm,
Indianapolis, IN, USA

Part I

Secondary Hereditary and Acquired Cardiac Channelopathies and Sudden Cardiac Death

Arthur A.M. Wilde, Michael J. Ackerman, Charles Antzelevitch,
and Ihor Gussak

A.A.M. Wilde, MD, PhD, FESC, FAHA
Department of Cardiology, Heart Center,
Academic Medical Center, University of Amsterdam,
Meibergdreef 9, 1105 AZ,
Amsterdam, The Netherlands

M.J. Ackerman, MD, PhD, FACC
Department of Medicine,
Division of Cardiovascular Diseases,
Department of Pediatric and Adolescent Medicine,
Division of Pediatric Cardiology,
Department of Molecular Pharmacology and
Experimental Therapeutics,
Mayo Clinic, Rochester, MN, USA
e-mail: ackerman.michael@mayo.edu,
haglund.carla@mayo.edu

C. Antzelevitch, PhD, FACC, FAHA, FHRS
Gordon K. Moe Scholar,
Masonic Medical Research Laboratory,
Utica, NY, USA

I. Gussak, MD, PhD, FACC
Ono Pharmaceutical USA,
Lawrenceville, NJ, USA

Department of Internal Medicine,
University of Medicine and Dentistry of New Jersey,
Robert Wood Johnson Medical School,
New Brunswick, NJ, USA
e-mail: igussak@hotmail.com

1

Introduction to Part Three: Cardiac Remodeling

N.A. Mark Estes III

The concept of remodeling of the heart has evolved to include a broad spectrum of inherited or acquired electrical and structural myocardial alterations that are important in the pathogenesis of multiple cardiac arrhythmias [1–3]. The rhythm abnormalities associated with myocardial diseases discussed in this section include those encountered with hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular dysplasia (ARVD), dilated cardiomyopathies (DCM), and skeletal myopathies. Functional electrophysiologic abnormalities frequently develop in association with structural and electrical remodeling with these myocardial diseases [1–3]. Also discussed in this section are functional cardiac alterations that can be inherited as channelopathies, such as the long QT syndromes (LQTS), catecholaminergic polymorphic ventricular tachycardia, Brugada Syndrome, and the early repolarization syndromes. These functional abnormalities of ion channels also can be acquired, as occurs with drug induced QT prolongation and resultant Torsades de Pointes. Brugada type pattern on the electrocardiogram represents another example of an acquired condition induced by pharmacologic agents. These and other abnormalities

of electrical activation are considered as forms of electrical remodeling, typically but not always, without significant structural remodeling. Thus when considered from the perspective of cardiac remodeling, the chapters in the section have a common thematic basis. These alterations of electrical depolarization, repolarization and myocardial structure assume clinical significance as they are mechanistically linked to a spectrum of cardiac arrhythmias [1–3]. Understanding the fundamental cellular and molecular mechanisms of remodeling is a requisite to identify novel therapeutic targets for the prevention or treatment of cardiac arrhythmias with the cardiac conditions discussed in this section [1–3].

The remodeling processes associated with HCM, ARVD, dilated cardiomyopathies and cardiac dysfunction associated with skeletal myopathies, as noted in the subsequent chapters are complex and only partially understood [1–4]. Mechanism based prevention and therapy for these conditions, as well as the channelopathies discussed in the ensuing chapters, are not possible with current knowledge [1–4]. Nevertheless, the application of current techniques of cellular and molecular biology has improved the understanding of the multiple factors causing anatomic and functional remodeling [1–4]. It also has resulted in insights into the complex interaction of underlying anatomic or functional substrate abnormalities with triggering mechanisms that determine whether arrhythmias will arise in association with these clinical conditions [1–4].

N.A.M. Estes III, MD
Department of Medicine,
Tufts University School of Medicine,
Boston, MA, USA

Tufts Cardiac Arrhythmia Center, Boston, MA, USA
e-mail: nestes@tuftsmedicalcenter.org